News | October 14, 2008

Cardiogenesis Hosts TCT Symposium on Cardiac Regenerative Medicine

October 15, 2008 - Cardiogenesis Corp. sponsored an educational symposium entitled "New Horizons in Cardiac Regenerative Medicine: Advancements in Revascularization & Stem Cell Therapy," this week in conjunction with the TCT meeting in Washington, D.C.

The symposium was attended by over 120 cardiology healthcare practitioners and chaired by Warren Sherman, M.D., director of Cardiac Cell Based Endovascular Therapies, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center. Presenters included: Emerson Perin, M.D., Ph.D, director, New Interventional Cardiovascular Technology, Texas Heart Institute; Marvin Slepian, M.D., director of Interventional Cardiology, University of Arizona, Sarver Heart Center; and Keith Allen, cardiothoracic surgeon, Mid America Heart and Thoracic Surgeons, Kansas City, MO.

"The program was designed to provide an update to clinicians on the recent developments with advanced cardiovascular revascularization and regenerative therapies, with a focus on patients suffering from ischemic cardiac disease," Dr. Sherman stated. "TCT attendees are eager to learn about rapidly evolving therapies, as well as the latest information on optimizing outcomes with available tools and techniques, including TMR [transmyocardial revascularization] as a sole therapy and adjunctive to bypass surgery."

"Surgeons are innovating with Cardiogenesis to provide TMR with minimally invasive approaches, including surgical robotic delivery,” said Dr. Allen. He also discussed the early clinical experience with the PHOENIX combination delivery system being collected from centers outside the U.S.

As a leading clinical investigator of autologous stem cell trials, Dr. Perin provided a state-of-the-art overview of cardiovascular stem cell clinical trials. "The tissue-stimulated zone generated by TMR, along with the precise delivery of stem cells, may prove to be more potent in combination than either therapy alone," he explained.

For more information: www.cardiogenesis.com

Related Content

New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies| May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
ischemic heart failure, stem cell therapy, MSCs, CSCs, Minneapolis Heart Institute Foundation, MHIF study
News | Heart Failure| January 10, 2017
Ischemic heart failure from previous heart attacks and coronary artery disease is the leading cause of death in the...
News | Stem Cell Therapies| January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
News | Stem Cell Therapies| January 03, 2017
January 3, 2017 — BioCardia Inc. announced in December the initiation of the CardiAMP Heart Failure pivotal trial, a
Overlay Init